Michael L. Schenker

23A Caracal St
Craiova, DJ 200347, Romania

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 116 publications

Colorectal Cancer Burden and Trends in South-West Oltenia, Romania: A 15-Year Real-World Study from a Regional Referral Cancer Center.

Colorectal Cancer Burden and Trends in South-West Oltenia, Romania: A 15-Year Real-World Study from a Regional Referral Cancer Center.

Journal: Cancers

Published: June 25, 2026

Multidisciplinary Management of Complicated Locally Advanced and Fungating Breast Cancer: A Narrative Review.

Multidisciplinary Management of Complicated Locally Advanced and Fungating Breast Cancer: A Narrative Review.

Journal: Cancers

Published: June 14, 2026

Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.

Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.

Journal: The New England journal of medicine

Published: May 27, 2026

Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L).

Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L).

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 14, 2026

A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer).

A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer).

Journal: Future oncology (London, England)

Published: April 15, 2026

Diagnostic accuracy and association with lymph node metastasis of the systemic immune-inflammation index in thyroid cancer: a systematic review and meta-analysis.

Diagnostic accuracy and association with lymph node metastasis of the systemic immune-inflammation index in thyroid cancer: a systematic review and meta-analysis.

Journal: Frontiers in immunology

Published: April 10, 2026

Corrigendum to "Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial": [Ann Oncol 36 (2025) 775-785].

Corrigendum to "Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial": [Ann Oncol 36 (2025) 775-785].

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 08, 2026

Continued Cemiplimab Beyond Progression With Addition of Chemotherapy in Patients With Advanced NSCLC With PD-L1 Expression of 50% or Higher: 5-Year Follow-Up From EMPOWER-Lung 1.

Continued Cemiplimab Beyond Progression With Addition of Chemotherapy in Patients With Advanced NSCLC With PD-L1 Expression of 50% or Higher: 5-Year Follow-Up From EMPOWER-Lung 1.

Journal: JTO clinical and research reports

Published: February 27, 2026

Gastrointestinal Toxicity and Clinical Predictors of Total Neoadjuvant Therapy in Rectal Cancer: A Real-World Retrospective Study.

Gastrointestinal Toxicity and Clinical Predictors of Total Neoadjuvant Therapy in Rectal Cancer: A Real-World Retrospective Study.

Journal: Life (Basel, Switzerland)

Published: February 04, 2026

Adverse Histopathological Features in Colorectal Cancer Associated with KRAS rs61764370 SNP: A Preliminary Study.

Adverse Histopathological Features in Colorectal Cancer Associated with KRAS rs61764370 SNP: A Preliminary Study.

Journal: Biomedicines

Published: December 30, 2025

Career challenges of young oncologists in Romania: a nationwide survey.

Career challenges of young oncologists in Romania: a nationwide survey.

Journal: BMC medical education

Published: December 02, 2025

ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC.

ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC.

Journal: Clinical lung cancer

Published: October 30, 2025

Showing 1-12 of 116

Last Updated: 09/26/2026